Anti-complement C1s antibodies and uses thereof
AssigneeBioverativ USA Inc.
InventorsPeter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
Claims13
A humanized antibody that binds complement C1s protein and comprises:
- a light chain variable region that comprises a CDR-L1 amino acid sequence set forth as SEQ ID NO:
- 32, a CDR-L2 amino acid sequence set forth as SEQ ID NO:
- 33, and a CDR-L3 amino acid sequence set forth as SEQ ID NO:
- 3;
- a heavy chain variable region that comprises a CDR-H1 amino acid sequence set forth as SEQ ID NO:
- 34, a CDR-H2 amino acid sequence set forth as SEQ ID NO:
- 35, and a CDR-H3 amino acid sequence set forth as SEQ ID NO:
- 36;
- and
- a human IgG4 constant region, wherein the human IgG4 constant region comprises a S241P substitution (by Kabat numbering) and an L235 E substitution (by EU numbering).
A method comprising administering to an individual a humanized antibody that binds complement C1s protein and comprises:
- a light chain variable region that comprises a CDR-L1 amino acid sequence set forth as SEQ ID NO:
- 32, a CDR-L2 amino acid sequence set forth as SEQ ID NO:
- 33, and a CDR-L3 amino acid sequence set forth as SEQ ID NO:
- 3;
- a heavy chain variable region that comprises a CDR-H1 amino acid sequence set forth as SEQ ID NO:
- 34, a CDR-H2 amino acid sequence set forth as SEQ ID NO:
- 35, and a CDR-H3 amino acid sequence set forth as SEQ ID NO:
- 36;
- and
- a human IgG4 constant region, wherein the human IgG4 constant region comprises a S241P substitution (by Kabat numbering) and an L235 E substitution (by EU numbering),
- wherein the individual has a complement-mediated disease.
A method of treating a complement-mediated disease in an individual, the method comprising administering to the individual a humanized antibody in an amount effective to treat the complement-mediated disease, wherein the humanized antibody binds complement C1s protein and comprises:
- a light chain variable region that comprises a CDR-L1 amino acid sequence set forth as SEQ ID NO:
- 32, a CDR-L2 amino acid sequence set forth as SEQ ID NO:
- 33, and a CDR-L3 amino acid sequence set forth as SEQ ID NO:
- 3;
- a heavy chain variable region that comprises a CDR-H1 amino acid sequence set forth as SEQ ID NO:
- 34, a CDR-H2 amino acid sequence set forth as SEQ ID NO:
- 35, and a CDR-H3 amino acid sequence set forth as SEQ ID NO:
- 36;
- and
- a human IgG4 constant region, wherein the human IgG4 constant region comprises a S241P substitution (by Kabat numbering) and an L235 E substitution (by EU numbering).
Dependencies are inferred from the claim text.